viernes, 7 de octubre de 2016
Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer | Cancer Currents Blog
Avelumab Shrinks Merkel Cell Tumors - National Cancer Institute
In a clinical trial, a new immunotherapy drug called avelumab has shown promise in patients with metastatic Merkel cell carcinoma, a rare, aggressive skin cancer with few effective treatments. In the phase II trial, 32% of patients with metastatic Merkel cell carcinoma that had returned after earlier treatment experienced partial or complete shrinkage of their tumors when treated with the new drug. Among patients whose tumors shrank, more than 90% sustained this response for at least 6 months.